Search research articles
Contact Us
Filters
Showing results (281-290 of 319) with videos related to
Page
of 32
Sort By:
ACS Nano
|
November 19, 2010
Electron paramagnetic resonance investigation of purified catalyst-free single-walled carbon nanotubes
Mujtaba Zaka, Yasuhiro Ito, Huiliang Wang, et al.
In Vivo (Athens, Greece)
|
April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Translational Andrology and Urology
|
September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Clinical Oncology
|
October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist
Ruengwit Kitbunnadaj, Takeshi Hashimoto, Enzo Poli, et al.
Experimental Physiology
|
July 28, 2021
Integrated respiratory chemoreflex-mediated regulation of cerebral blood flow in hypoxia: Implications for oxygen delivery and acute mountain sickness
Shigehiko Ogoh, Takuro Washio, Benjamin S Stacey, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
December 19, 2023
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
Wataru Fukuokaya, Yuhei Koike, Yuji Yata, et al.
Urologic Oncology
|
May 5, 2019
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan
Takuya Tsujino, Kazumasa Komura, Takeshi Hashimoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study
Takuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Page
of 32
Search research articles
Search
Showing results (281-290 of 319) with videos related to
Sort By:
Page
of 32
ACS Nano
|
November 19, 2010
Electron paramagnetic resonance investigation of purified catalyst-free single-walled carbon nanotubes
Mujtaba Zaka, Yasuhiro Ito, Huiliang Wang, et al.
In Vivo (Athens, Greece)
|
April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab Vedotin
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate Cancer
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Translational Andrology and Urology
|
September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab
Mamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Clinical Oncology
|
October 1, 2024
Real-world outcomes in patients with metastatic castration-resistant prostate cancer beyond progression after upfront androgen receptor signaling inhibitor
Yutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Journal of Medicinal Chemistry
|
March 18, 2005
N-substituted piperidinyl alkyl imidazoles: discovery of methimepip as a potent and selective histamine H3 receptor agonist
Ruengwit Kitbunnadaj, Takeshi Hashimoto, Enzo Poli, et al.
Experimental Physiology
|
July 28, 2021
Integrated respiratory chemoreflex-mediated regulation of cerebral blood flow in hypoxia: Implications for oxygen delivery and acute mountain sickness
Shigehiko Ogoh, Takuro Washio, Benjamin S Stacey, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
December 19, 2023
Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study
Wataru Fukuokaya, Yuhei Koike, Yuji Yata, et al.
Urologic Oncology
|
May 5, 2019
C-reactive protein-albumin ratio as a prognostic factor in renal cell carcinoma - A data from multi-institutional study in Japan
Takuya Tsujino, Kazumasa Komura, Takeshi Hashimoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study
Takuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Page
of 32